<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pilocarpine (ophthalmic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pilocarpine (ophthalmic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pilocarpine (ophthalmic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9903" href="/d/html/9903.html" rel="external">see "Pilocarpine (ophthalmic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12289" href="/d/html/12289.html" rel="external">see "Pilocarpine (ophthalmic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9505057"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Isopto Carpine [DSC];</li>
<li>Vuity</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869964"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Isopto Carpine;</li>
<li>Minims Pilocarpine Nitrate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10512786"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Cholinergic Agent</span>;</li>
<li>
<span class="list-set-name">Cholinergic Agent, Ophthalmic</span>;</li>
<li>
<span class="list-set-name">Ophthalmic Agent, Miotic</span></li></ul></div>
<div class="block dop drugH1Div" id="F46361386"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef6b98ca-2844-41c4-83df-3ce72b393368">Glaucoma, open-angle; reduction of elevated intraocular pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glaucoma, open-angle; reduction of elevated intraocular pressure (IOP):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: 1% solution: Ophthalmic: Instill 1 drop into the affected eye(s) 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: 1%, 2%, or 4% solution: Ophthalmic: Instill 1 drop into the affected eye(s) up to 4 times daily. <b>Note:</b> Strength of solution and frequency of instillation dependent on degree of pressure elevation and patient miotic response; individualize therapy; for pilocarpine-naive patients, initiate therapy with the 1% concentration.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ec30927f-3af1-4502-9592-ec1e12ada435">Glaucoma, acute angle closure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glaucoma, acute angle closure:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: 1% solution: Ophthalmic: Instill 1 drop into the affected eye(s) 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: 1% or 2% solution: Ophthalmic: Initial: Instill 1 drop into the affected eye(s) up to 3 times over a 30-minute period; pretreatment with secretory suppressant and hyperosmotic agent may be required to lower IOP below 50 mm Hg and relieve iris ischemia. If laser iridoplasty or iridotomy required to break the attack, instill 1 drop of 4% solution prior to the procedure; following laser iridoplasty, instill 1 drop of 1% solution 4 times daily until an iridotomy can be performed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94ad1b35-5b5f-4f98-819b-57088acf3083">Miosis induction; prior to goniotomy or trabeculectomy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Miosis induction; prior to goniotomy or trabeculectomy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: 1% or 2% solution: Ophthalmic: Instill 1 drop into the eye(s) 15 to 60 minutes prior to surgery.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51153605"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153606"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F9505229"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9903" href="/d/html/9903.html" rel="external">see "Pilocarpine (ophthalmic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60f91e7f-5b7f-4b65-8d79-2634ab361d31">Elevated intraocular pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Elevated intraocular pressure:</b>
<b>Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Open-angle glaucoma or ocular hypertension</i>: 1%, 2%, 4% solution: Instill 1 drop into the affected eye(s) up to 4 times daily; initiate pilocarpine-naive patients on the 1% concentration. <b>Note:</b> Strength of solution and frequency of instillation dependent on degree of pressure elevation and patient miotic response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Angle-closure glaucoma, acute</i>: 2% solution: Instill 1 drop into the affected eye as part of a 4-drug regimen; may repeat in 30 to 60 minutes if intraocular pressure remains elevated (eg, &gt;40 mm Hg). <b>Note</b>: Reserve medical management for emergency situations when an assessment by an ophthalmologist will be delayed by ≥1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17910297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17910297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="84bc4f4c-1176-4ee7-a6df-2d057cb62d43">Miosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Miosis:</b>
<b>Ophthalmic:</b> 1%, 2%, 4% solution: Instill 1 drop (or 2 drops 5 minutes apart) into the affected eye(s).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a110fe7c-5ffc-4cdc-a2e7-d99258707117">Presbyopia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Presbyopia: Ophthalmic:</b> 1.25% solution: Instill 1 drop into each eye once daily; 1 additional drop may be instilled into each eye 3 to 6 hours after the first dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d0815c02-58cd-4c19-9aa4-4570fe48c033">Prevention of postoperative elevated intraocular pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of postoperative elevated intraocular pressure:</b>
<b>Ophthalmic:</b> 1%, 2%, 4% solution: Instill 1 drop (or 2 drops 5 minutes apart) into the affected eye(s) 15 to 60 minutes prior to surgery.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990155"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987488"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9505079"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, blurred vision, conjunctival hyperemia, eye irritation, eye pain, increased lacrimation, supraorbital pain, visual impairment (including dim, dark, or jumping vision), vitreous opacity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Ophthalmic: Retinal detachment, retinal hole without detachment, vitreous detachment, vitreous traction</p></div>
<div class="block coi drugH1Div" id="F9505071"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Isopto Carpine: There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Hypersensitivity to pilocarpine or any component of the formulation; conditions where pupillary constriction is undesirable (eg, acute iritis, anterior uveitis).</p>
<p style="text-indent:-2em;margin-left:2em;">Vuity: Hypersensitivity to pilocarpine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F9505072"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic effects: Miotics may cause accommodative spasm, as well as temporary dim or dark vision. Do not drive if vision is not clear; use caution when driving at night and other hazardous activities in poor illumination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: In a scientific statement from the American Heart Association, ophthalmic cholinergic agents have been determined to be agents that may exacerbate underlying myocardial dysfunction (magnitude: minor) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular inflammation: Use is not recommended when iritis is present. Avoid miotics in acute inflammatory diseases of the anterior chamber.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal disease: Rare cases of retinal detachment and retinal tear have been reported; patients with preexisting retinal disease are at increased risk. Sudden onset of flashing lights, floaters, or vision loss should be reported immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in pediatric patients with primary congenital glaucoma for control of intraocular pressure (IOP); cases of paradoxical increase in IOP have been reported. Use is not recommended in pediatric patients diagnosed with glaucoma secondary to anterior segment dysgenesis or uveitis (especially if uveitis is active).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: May contain benzalkonium chloride, which may be adsorbed and cause discoloration of soft contact lenses; remove contacts prior to administration and wait 10 minutes before reinserting.</p></div>
<div class="block prod-avail drugH1Div" id="F58745539"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Qlosi 0.4% ophthalmic solution: FDA approved October 2023; availability anticipated in the first half of 2024. Information pertaining to this product within the monograph is pending revision. Qlosi is indicated for the treatment of presbyopia in adults. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F9505257"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isopto Carpine: 1% (15 mL [DSC]); 2% (15 mL [DSC]); 4% (15 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vuity: 1.25% (2.5 mL, 5 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (15 mL); 2% (15 mL); 4% (15 mL)</p></div>
<div class="block geq drugH1Div" id="F9505060"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9505259"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pilocarpine HCl Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $6.18 - $6.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $6.32 - $6.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $6.63 - $7.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vuity Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25% (per mL): $37.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869965"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isopto Carpine: 2% (15 mL); 4% ([DSC]) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% ([DSC]); 2% ([DSC]); 4% ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as nitrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (0.3 mL)</p></div>
<div class="block admp drugH1Div" id="F52614401"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: For ophthalmic use only. Solution: Instill into affected eye(s); apply finger pressure to lacrimal sac for 2 minutes after instillation to decrease drainage into the nose and throat and minimize possible systemic absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>). Remove contact lenses prior to instillation and wait ≥10 minutes before reinserting. Separate administration of other ophthalmic agents by ≥5 minutes. Do not touch the tip of the dropper to the eye, fingertips, or other surface.</p></div>
<div class="block adm drugH1Div" id="F9505233"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic:</b> Gently apply finger pressure to the lacrimal sac for 2 minutes following administration. Remove contact lenses prior to instillation and wait 10 minutes before reinserting. In most cases, separate administration of other ophthalmic agents by at least 5 minutes. When treating acute angle-closure glaucoma, separate administration of other ophthalmic agents by ≥1 minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17910297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17910297'])">Ref</a></span>). Do not touch the tip of the dropper to the eye, fingertips, or other surface.</p></div>
<div class="block sts drugH1Div" id="F9505098"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Isopto Carpine: Store at 20°C to 25°C (68°F to 77°F); excursion permitted between 15°C to 30°C (59°F to 86°F). Protect from freezing.</p>
<p style="text-indent:-2em;margin-left:2em;">Vuity: Store at 15°C to 25°C (59°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53570729"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">1%, 2%, or 4% solution: Reduction of elevated intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension (FDA approved in pediatric patients [age not specified] and adults); management of acute angle-closure glaucoma (FDA approved in pediatric patients [age not specified] and adults); induction of miosis (FDA approved in pediatric patients [age not specified] and adults); and prevention of postoperative elevated IOP associated with laser surgery (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">1.25% solution: Treatment of presbyopia (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F9505047"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Isopto Carpine may be confused with Isopto Carbachol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9505084"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9505087"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cyclopentolate: May diminish the therapeutic effect of Pilocarpine (Ophthalmic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tropicamide: May diminish the therapeutic effect of Pilocarpine (Ophthalmic).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F9887312"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block mopp drugH1Div" id="F53570722"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure, funduscopic exam (before therapy initiation), visual field testing.</p></div>
<div class="block pha drugH1Div" id="F9505100"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Directly stimulates cholinergic receptors in the eye causing miosis (by contraction of the iris sphincter), loss of accommodation (by constriction of ciliary muscle), and lowering of intraocular pressure (with decreased resistance to aqueous humor outflow)</p></div>
<div class="block phk drugH1Div" id="F9505104"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Miosis: 10 to 30 minutes; Intraocular pressure reduction: 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Miosis: 4 to 8 hours; Intraocular pressure reduction: 4 to 14 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962002"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apicarpin | Isopto Carpine | Minims pilocarpine nitrate | Pilocarpine | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alvis | Isopto carpina | Klonocarpina | Omaclopil | Pilocarpina poen | Pilocarpol | Pilomed | Sonadryl</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Piloftal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Minims pilocarpine | P v carpine | Pilocarpine | Pilocarpine neut | Pilocarpine nitrat | Pilopt</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Optacarpine | Pilocarpine | Pilodrop | Pilomin | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Chibro pilocarpine | Isopto Carpine | Pilo | Pilocarpine isopto | Pilocarpine nitr chauvin benelux</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Pilocarpin augenoe | Pilocarpin vision | Pilocarpinum Hydrochloricum</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pilocan | Pilocarpina | Pilosol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pilo | Pilocarpine SDU Faure | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Isopto Pilocarpina | Pilocarpina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bei ni te | Le qing | Pilocarpine | Zhen rui</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Isopto carpina | Isopto Carpine</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pilocarpin | Pilopos | Pilotonina</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Borocarpin -S | Pilo stulln | Pilocarpin | Pilocarpin ankerpharm | Pilomann | Pilopos | Spersacarpin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pilocar | Pilocarpina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pilocarpina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Oftan-pilocarpin | Pilocarpin | Pilocarpine | Pilocarpini | Pilomann</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Ocucarpine | Pilocarpine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Colircusi Pilocarpina | Isopto carpina</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Minims pilocarpine nitrate | Oftan-pilocarpin | Oftan-pilotard | Pilodur | Pv carpine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Chibro pilocarpine | Isopto pilocarpine | Pilo | Pilocarpine Chlorhydrate pch | Pilocarpine faure</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pilocarpine | Pilocarpine cox | Pilocarpine cusi | Pilocarpine dc | Pilocarpine kent | Sno pilo</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dispercarpine | Isopto Carpine | Pilocollyre</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Minims pilocarpine nitrate | Pilocarpine</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Pilokarpin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Humacarpin | Isopto Carpine | Pilocarpin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Carpinol | Cendo carpine | Miokar | Pilokarpin | Pv carpine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Isopto pilocarpine | Pilocarpine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Glaucocarpine | Mi-Pilo | Pilocarpine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Andre carpine | Carpine | Carpinol | Carpo-miotic | Carporen | Locarp | Opthocarpine | Pilagan | Pilocar | Pilodrops | Pilomin | Pilopress</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dropilton | Pilocarpina | Pilocarpina farmigea</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Apicarpin | Isopto Carpine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Adsorbocarpine | Isocarpine | Metocarpine | Pyrolina | Sanpilo</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ivycarp | Pilo</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Isoptocarpine | Ocucarpine | Pilocarpine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Minims pilocarpine nitrate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Isopto pilocarpine | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Oftan pilocarpine | Pilocarpin | Pilocarpin v | Pilocarpine | Pilomann | Spersacarpin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Asthenopin | Isopto Carpine | Pilocarpine isopto | Pilomann | Spersacarpin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Oftan pilocarpine | Pilocarpin | Spersacarpin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Pilo</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dretinof | Pil ofteno | Pilo grin | Pilocarpina | Pilof nicolich</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pv carpine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Kinglion pilocarpine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pilocarpine HCL | Pilocarpine HCl PCH | Pilocarpinehydrochloride ratiopharm | Pilocarpinehydrochloride teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pilo | Pilocarpina | Pilocarpine | Pilocarpine HCL akorn | Pilokarpin | Pilokarpin minims | Pilokarpin naf sykehusapoteket</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Minims pilocarpine | Ocusert pilo | Pilopt</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Isopto carpina | Locarpin F | Pilocarpina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ethicar | Isopto Carpine | Medicarpine | Normoglaucon | Opta Carpine | Orbacarpine | Pilocar | Pilocarpine | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pilocarpin | Pilocarpinum hcl | Pilocarpinum hec | Pilogel | Pilomann | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Pilocar | Pilocarpine HCL | Piloptic | Vuity</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Colircusi Pilocarpina | Pilo | Pilocarpina | Piloplex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Isopto carpina | Pilocarpina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Pilotina-2</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Apicarpin | Borocarpin s | Dropil | Isopto Carpine</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Isopto carpin | Oftan pilocarpine | Pilocarpin | Pilocarpine ferein | Pilocarpine with methylcellulose</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apicarpin | Isopto Carpine | Pilocarpine | Pilotina</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Isopto-pilokarpin | Licarpin | Pilokarpin ccs | Pilokarpin Trimb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Minims pilocarpine | Minims pilocarpine nitrate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pilocarpin | Pilokarpin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Pilocarpin | Pilokarpin V</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | P.v. carpine | Pilocarpine | Pilomann | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Apicarpin | Isopto pilocarpine | Pilocarpine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pilokarsol | Pilomin | Pilosed</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Colircusi Pilocarpina | Isopto Carpine | Pilocarpine | Pilocarpine HCL | Sanpilo | Spersacarpine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Oftan pilocarpine | Pilocarpin | Pilocarpinum hcl</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Isopto carpina | Pilocarpina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Isopto carpina | Pilocar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Isopto Carpine | Minims pilocarpine</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ivycarp | Pilocar eye drops</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Isopto.1">
<a name="Isopto.1"></a>Isopto Carpine (pilocarpine hydrochloride) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isopto.2">
<a name="Isopto.2"></a>Isopto Carpine (pilocarpine hydrochloride) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2205180">
<a name="2205180"></a>Krawitz PL, Podos SM. Use of apraclonidine in the treatment of acute angle closure glaucoma. <i>Arch Ophthalmol</i>. 1990;108(9):1208-1209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-ophthalmic-pediatric-drug-information/abstract-text/2205180/pubmed" id="2205180" target="_blank">2205180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure: a ccientific statement from the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-ophthalmic-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17910297">
<a name="17910297"></a>Pokhrel PK, Loftus SA. Ocular emergencies [published correction appears in: <i>Am Fam Physician</i>. 2008;77(7):920]. <i>Am Fam Physician</i>. 2007;76(6):829-836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-ophthalmic-pediatric-drug-information/abstract-text/17910297/pubmed" id="17910297" target="_blank">17910297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Vuity (pilocarpine hydrochloride) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs.<i> Arch Ophthalmol</i>. 1984;102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16042 Version 209.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
